KRAS and non-small cell lung carcinoma: For instance, in a study involving patients with non-squamous NSCLC treated with pembrolizumab alone or in combination with chemotherapy, those with KRAS mutations had a longer PFS compared to patients with wild-type KRAS (median PFS 16.5 months vs. 8.0 months) (55).